Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials. J of Skin. 2025;9(1):s522. doi:10.25251/skin.9.supp.522